Daida alberto armas

Daida alberto armas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Pharmacy
Verified
Journal Article
Open access
PDF file
DADaida alberto armas
Daida alberto armas
JAJuan Ramón Santana Ayala
Juan Ramón Santana Ayala
JAJuan Ramón Santana Ayala
Juan Ramón Santana Ayala
Arturo HardissonArturo Hardisson
Arturo Hardisson
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Users of benzodiazepines (BZDs) should have their quality of life monitored to minimize the risks associated with long-term treatments. The aim of this study is to use the EuroQol 5D-3L to analyze the quality of life of 127 patients under treatment with BZDs during the COVID-19 pandemic. The results show that lorazepam comprises 25.49% of all dispensing requests, and that the mean duration of BZDs treatments is four years (range: 0.3–25). When rating their general health status, BZDs users reported 59.29 points out of 100. Thirty-two percent of patients reported mobility problems; 16.5% reported having a lot of pain or discomfort despite being treated with BZDs, and 16.54% used a BZD together with an opioid analgesic. The EuroQol 5D-3L dimension “anxiety/depression” showed that, despite the use of BZDs, 48.2% of the patients reported being moderately anxious or depressed and 13.4% described themselves as very anxious or depressed. Nevertheless, 37.8% of BZDs users were identified as potential candidates to follow a BZD deprescription plan. In conclusion, BZDs users showed a low quality of life during the COVID-19 pandemic. Older patients and females have been identified as groups of patients that could benefit from integrating the use of the EuroQol 5D-3L instrument into the protocols of the pharmaceutical care follow up.

31 July 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
DADaida alberto armas
Daida alberto armas
VGVeronica Hernandez Garcia
Veronica Hernandez Garcia
YCYanira Román Castillo
Yanira Román Castillo
JAJuan Ramón Santana Ayala
Juan Ramón Santana Ayala
FFFranc capdevila finestres
Franc capdevila finestres
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Background: Tolerance and dependence stand out as the most relevant risks observed during benzodiazepine (BZD) treatments. Objectives: To evaluate the degree of dependence of patients on BZD treatments using the Tyrer test; to define a profile of patients at risk of developing BZD dependence; and to discuss the role of the pharmaceutical care offered by the community pharmacy during dispensing. Methods: Prospective cross-sectional descriptive observational study (August 2020–February 2021) involving 127 patients using BZD. They voluntarily answered a questionnaire during the dispensing pharmaceutical care service. The study was evaluated and codified (code: DAA-CLO-2020-01) by the Spanish Agency for Drugs and Health Products (AEMPS), and statistical analysis was performed with SPSS 25.0. Results: 19.05% of patients using BZD were suspected of suffering from BZD tolerance, and 77.88% of all patients were identified as being at a high risk of BZD dependence. The Tyrer test for dependence indicated a mean score of 5.59 out of 13 points. An 18-fold increased risk of developing dependence was detected in the case of coexistence of high anxiety or depression. Conclusions: The community pharmacy, through protocolized care practices and supported by tools such as the Tyrer test, can play a decisive role in the detection, prevention, and resolution of the risks associated with BZD treatments.

11 December 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
JAJuan Ramón Santana Ayala
Juan Ramón Santana Ayala
DADaida alberto armas
Daida alberto armas
VGVeronica Hernandez Garcia
Veronica Hernandez Garcia
AAArmando Aguirre-Jaime
Armando Aguirre-Jaime
Ángel J. GutiérrezÁngel J. Gutiérrez
Ángel J. Gutiérrez
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Introduction: During pharmaceutical care, community pharmacists play a crucial role by carrying out interventions aimed at preventing, detecting, and resolving drug-related problems (DRPs) and negative outcomes associated with medication (NOM), simultaneously enhancing patients’ knowledge about their treatments. The chronic use of Benzodiazepines (BZDs) is known to be associated with risks such as tolerance, dependence, and cognitive impairment. Furthermore, the combined use of BZDs with other medications or alcohol may expose patients to significant drug interactions. Objectives: This study aimed to characterize and describe the clinical profile of patients using BZDs, to evaluate the extent of polypharmacy and potential drug interactions, to investigate their level of knowledge regarding BZD treatment, and ultimately, to propose evidence-based interventions from the community pharmacy to contribute to improving patient safety and minimizing risks associated with BZD use. Method: A cross-sectional, descriptive study was conducted in a single community pharmacy in Gran Canaria (Canary Islands, Spain). The study population comprised 125 adult patients with active BZD prescriptions. Data collection was performed through pharmacist–patient structured interviews using a questionnaire that included sociodemographic, clinical, and BZD knowledge variables. Results: Lormetazepam and alprazolam were the BZDs most frequently prescribed and dispensed. Potential drug interactions with other medications were detected in 38.4% of BZD users. Notably, 61.5% of patients using BZDs also reported the concurrent use of opioid analgesics, with tramadol being the most common opioid (48.1% of BZD users were also treated with tramadol). Statistically significant differences were observed between patients with and without BZD and other drug interactions in several adverse outcome variables, including the risk of falls (p = 0.003), cognitive impairment (p = 0.047), and urinary incontinence (p = 0.016). Existing BZD dependence is detected in 25% and 22.1% of cases, respectively. Patients’ knowledge of their BZD treatment revealed critical gaps, which are identified as a challenge and a clear opportunity for intervention through pharmaceutical care services. Conclusions: The findings underscore the essential and proactive role of community pharmacists in identifying and managing drug interactions, as well as in supporting deprescribing strategies through collaborative and interprofessional care models.

9 March 2026 in Foods
Verified
Journal Article
Open access
PDF file
Juan Ramón Jáudenes-MarreroJuan Ramón Jáudenes-Marrero
Juan Ramón Jáudenes-Marrero
Ángel J. GutiérrezÁngel J. Gutiérrez
Ángel J. Gutiérrez
CMChaxiraxii Morales Marrero
Chaxiraxii Morales Marrero
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Soraya Paz MontelongoSoraya Paz Montelongo
Soraya Paz Montelongo
DADaida alberto armas
Daida alberto armas
One of the most popular food supplements among the Canary population for the treatment of insomnia and mild anxiety is Valeriana officinalis L. (valerian), whose organ of use is the root. However, this plant is susceptible to the accumulation of certain metals, and a daily multi-dose treatment may be a dosage indication/regimen as multidose therapy. Therefore, there is an interest in determining its content of metals (Cd, Pb, Al, Cr, Cu, Li, Ni, Sr, Mo, Zn, Co, Fe, B, Mn, V, Ba, K, Na, Mg, Ca) to establish the possible toxicological risk of its consumption. The concentrations were determined by inductively coupled plasma optical emission spectrometry (ICP-OES) in a total of 23 samples (8 fragmented, 7 crushed, 8 pulverized). The Cd limit set by the European Pharmacopoeia (0.1 mg/kg) is more than doubled in six samples. The results showed that Pinisan (0.11 mg/kg), the EnRelax® pill (0.12 mg/kg), the EnRelax® infuser (0.13 mg/kg), Kneipp (0.15 mg/kg), Milvus (0.16 mg/kg) and one of the market samples (0.23 mg/kg) all exceed this parameter. However, the use of valerian root as a herbal plant or food supplement at therapeutic doses and in all studied dosages does not pose a toxicological risk based on the Estimated Daily Intake (EDI) of metals.

4 February 2025 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
FFFranc capdevila finestres
Franc capdevila finestres
DADaida alberto armas
Daida alberto armas
AMAntoni Miró Manzano
Antoni Miró Manzano
VGVeronica Hernandez Garcia
Veronica Hernandez Garcia
YAYeray Sosa Alonso
Yeray Sosa Alonso
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Introduction: Omeprazole is commonly prescribed for conditions associated with excess gastric acid, including gastroesophageal reflux and Helicobacter pylori infection. Spain ranks highest among Organization for Economic Co-operation and Development (OECD) countries in omeprazole consumption (measured in doses per 1000 inhabitants per day, DHD), indicating potential overuse and misuse. Community pharmacists are pivotal in collaborating with healthcare professionals to address safety risks and improve patient outcomes. Objective: This study aims to profile omeprazole users to inform pharmaceutical care (PC) strategies that address patient-specific needs and improve treatment safety. Methods: We conducted an observational, cross-sectional study (CEIm Code FCF-OME-2023-01) involving 100 omeprazole users at a community pharmacy in Barcelona from November 2023 to May 2024. Data were collected via clinical interviews using a Data Collection Questionnaire. Results: Among the omeprazole users, 49% were male, 51% female, and 56% were over the age of 65. A significant proportion (71%) exhibited long-term omeprazole use, and 30% were polymedicated (taking five or more medications). Notably, 52% of patients reported no history of gastric symptoms. Additionally, 22% reported using omeprazole occasionally, following short-term, on-demand treatment regimens, while 78% adhered to a chronic daily dosing schedule. Among these patients, 29.5% demonstrated poor treatment adherence. The analysis of medication-related problems (MRPs) among the 78 patients using omeprazole daily and chronically revealed that the most prevalent MRPs were “unnecessary medication”, “lack of adherence”, “wrong administration”, “drug interactions”, and “lack of knowledge regarding medication use”. Based on STOPP criteria, 45% of users were candidates for deprescribing or dose adjustment. Conclusions: The high incidence of MRPs among omeprazole users highlights the need for enhanced pharmaceutical care (PC). Proactive pharmacist interventions, including deprescribing, dose adjustments, and prescriber collaboration, can reduce adverse medication outcomes and promote safer omeprazole use.

1 January 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
LGL Santiago Gutiérrez
L Santiago Gutiérrez
DADaida alberto armas
Daida alberto armas
VGVeronica Hernandez Garcia
Veronica Hernandez Garcia
JAJuan Ramón Santana Ayala
Juan Ramón Santana Ayala
Roberto García SánchezRoberto García Sánchez
Roberto García Sánchez
Carmen Rubio ArmendárizCarmen Rubio Armendáriz
Carmen Rubio Armendáriz
Substance use disorder (SUD) is a chronic and clinically complex condition, frequently complicated by significant organic and psychiatric comorbidities. Most patients are polymedicated and require opioid substitution programs (OSPs). This complexity is further exacerbated by drug–drug interactions, therapeutic duplication, and fragmentation of the healthcare system. This retrospective observational study analyses the prevalence of polypharmacy and associated pharmacotherapeutic risks in a cohort of 1050 patients with SUD treated at Drug Care Units (DCUs) in Tenerife (Canary Islands, Spain). Prescriptions were dominated by methadone (62%), antidepressants, and antipsychotics, often in combination with benzodiazepines. Significant polypharmacy (>10 active prescriptions) was observed in 2.3% of patients, while 8.1% received 6–10 medications and 37.2% were using 2–5 medications. Women showed a higher pharmacological burden, with 3.5% experiencing significant polypharmacy (>10 different prescriptions) compared with 1.1% of men. Overall, 31% of patients received antidepressants, 31% were treated with antipsychotics—frequently with concurrent use of multiple agents—and 6.4% received opioids outside the OSP. Therapeutic duplication was observed in 15.6% of patients for psycholeptics, 14.2% for psychoanaleptics, and 3.2% for antiepileptics. Additionally, 25.2% of patients reported self-medication, predominantly with benzodiazepines. These findings underscore the need for integrated pharmaceutical care programs incorporating individualized therapeutic review and deprescribing strategies to enhance the safety and efficacy of SUD treatment.